Antimicrobial peptides (AMPs) are small cationic molecules best known as 24 cancer agent, as well as a mechanism that explains tumour cell sensitivity to 35
Introduction 39
Vast amount of evidence demonstrates the key role of systemic 40 immunity in tumour progression and patient outcome. Efforts to manipulate 41 the immune response to tumours are at the core of basic and translational 42 cancer research. In mammals and flies, tumourigenesis triggers inflammation 43 and activation of the immune system, leading to tumour cell death (Cordero et 2018). Moreover, using disc large 1 Drosophila mutant larvae (dlg 40.2 hereafter 54 referred to as dlg), we recently reported that tumour-derived Egr, acts on 55 haemocytes to activate Toll pathway in the Drosophila fat body, which was 56 necessary to mediate TNF-dependent tumour cell death (Parisi et al., 2014) . 57 However, the mechanisms by which Toll signalling activation in immune 58 tissues executes tumour cell death remain unknown ( Figure 1A) . 59
In Drosophila as in mammals, Toll pathway is well known to play a 60 central role in the innate immune response to infection (Lemaitre et al., 1996) . 61
Downstream effectors of the Toll pathway include antimicrobial peptides 62
(AMPs), which possess microbicidal activities against various pathogens. 63
They display potent antimicrobial activity in vitro by disrupting negatively-64 charged microbial membranes. While intracellular activities have been 65
reported, many AMPs kill pathogens by inserting into the lipid bilayer and 66 disrupting the membrane integrity (Brogden, 2005) . Host cells are instead 67
protected from AMP as they are positively charged and contain cholesterol 68 (Brender et al., 2012) . In vitro studies have revealed AMPs capacity to kill 69 cancer cells (Deslouches and Di, 2017) . However, whether this cancer-killing 70 activity is a natural function of AMPs is unknown, as there are no reports on 71 an in vivo paradigm addressing such question. Since the Toll pathway is 72 activated in dlg mutant tumour bearing larvae and is required for optimal TNF-73 induced tumour cell death (Parisi et al., 2014) , we hypothesised that AMPs 74 may be involved in this process. 75
Here we show that Drosophila defensin is induced in the fat body and 76 tracheal system of dlg mutant tumour bearing larvae. We find Defensin 77 consistently associated to dying tumour cells. Critically, systemic and tissue 78 specific knockdown of Defensin demonstrates a non-redundant role of the 79 AMP in controlling tumour growth through the induction of tumour cell death. 80
Anti-tumoural Defensin production relies on TNF-dependent activation of both 81
Toll and Imd pathway. Our results demonstrate that dlg mutant tumours 82 expose PS in response to haemocyte-derived TNF and that Defensin is 83 present in PS enriched area on the tumour surface. Finally, we find that lack 84 of TNF prevents tumour PS exposure and makes them insensitive to the 85 action of Defensin. Collectively, our results reveal an anti-tumoural role for 86
Defensin in vivo and provide insights into the molecular mechanisms, which 87 make tumours sensitive to the killing action of an endogenous AMP. In order to assess expression of several AMPs we performed RT-92 qPCR analysis on fat bodies dissected from wild type controls (w 1118 ) or dlg 93 mutant larvae ( Figure 1B) . Results showed consistent and statistically 94 significant upregulation of defensin in fat bodies of dlg larvae compared to 95 wild-type ones ( Figure 1B ). Other Toll-dependent AMPs display a trend to be 96 increased (drosomycin and attacin A), even though data was highly variable 97 amongst biological replicates, while other AMPs were not transcriptionally 98 regulated (drosocyn, cecropin A1) ( Figure 1B) . Interestingly, human β-99
Defensin 1 displays anticancer activity in vitro (Bullard et al., 2008; Sun et al., 100 and adipose tissue, and the trachea, a network of tubes transporting oxygen 151 to cells that resembles the mammalian vasculature, were the main sources of 152 defensin in these animals ( Figure 3A) . This was also supported by Defensin 153 immunostaining, which detected AMP expression in the fat body ( Figure 3B ), 154 and tumour-associated ( Figure 3C ) and tumour-distant trachea ( Figure 3D) . 155
Transcript assessment upon targeted IR knock down of defensin in the 156 respective tissues further confirmed the various domains of endogenous gene 157 expression ( Figure 3E and J). Importantly, knocking down defensin 158 expression specifically in the fat body or the trachea of dlg animals, resulted in 159 increased tumour size and decreased tumour cell death ( Figure 3F -I' and K-160 N') confirming the non-redundant functional requirement of defensin in both 161 tissues to efficiently promote tumour cell death. 162
To further investigate the possibility that Defensin produced by the fat 163 body and the trachea can specifically target tumour cells, we made use of an 164 inducible haemagglutinin (HA) tagged form of Defensin (UAS-def-HA). We 165 noticed leaky HA protein expression in the tracheal system of animals 166 carrying the UAS-def-HA construct only ( Figure 4A and B), while no staining 167 was detected in tissues from wild type larvae (data not shown). Therefore, 168
expressing UAS-def-HA in the fat body using a Gal4 specific driver (lpp>def-169 HA) resulted in detectable protein expression in both the trachea and the fat 170 body ( Figure 4C and D) . Strikingly, immunostaining revealed the presence of 171
Defensin-HA in transformed imaginal discs from dlg mutant animals ( Figure  172 4E and E') but not in normal tissues from heterozygous animals ( Figure 4F  173 and F'). 174
Consistently, using anti-Defensin antibody, we observed Defensin 175 staining on dlg mutant tumour ( Figure 4G -H'') but not in the wild-type discs 176 ( Figure 4I ). Interestingly, we predominantly observed Defensin bound to 177 tumour areas enriched with apoptotic cells ( Figure 4H-H'' ). High-resolution 178 imaging showed Defensin enrichment at the membrane of these dying cells 179
Altogether, these results show that Defensin produced by the trachea 181 and fat body selectively binds tumour cells to target them for apoptosis. showed that Toll pathway activation in dlg mutant larvae is required to achieve 188 maximal tumour cell death (Parisi et al., 2014) , the involvement of the Imd 189 pathway in tumour bearing animals was still elusive. To assess the 190 contribution of the Imd pathway to both defensin expression and tumour 191 burden, we analysed these two phenotypes in larvae deficient for the pathway. We observed a 55-60% decrease in defensin expression in dlg 193 mutants carrying a loss of function allele affecting imd (dlg;imd 1 ) ( Figure 5A TNF pathway leading to PS exposure ( Figure 7N ). This is followed by a 303 humoral response achieved by the action of antimicrobial peptides remotely 304 produced by the fat body and the trachea ( Figure 7N) . Thus, the two branches 305
of Drosophila innate immunity contribute to tumour elimination. 
Quantification of tumour volume and tumour cell death 490
For analysing tumour phenotype, images were acquired using optimal 491 slice parameter and 12bits using a Zeiss 710 confocal microscope. 492
Quantifications were made as previously described (Parisi et al., 2014) . 493
Briefly, we used Volocity 3D imaging analysis software (Perkin Elmer) to 494 quantify the total volume of tumour identified by DAPI staining and cell death 495 visualised with anti-Dcp1 staining. When haltere or leg discs tumours were 496 still associated with the wing disc, they were not considered for quantification. 497
Quantifications were done in at least three independent biological replicates 498 for each genetic setting. Single representative experiments are presented 499 except for dlg;def double mutant rescue experiments ( Figure 1L-M) for which 500 replicates are pooled due to the few larvae available. In all cases the 501 difference between control and mutant tumour were strongly reproducible 502 between replicates. 503 504
Sterile rearing conditions 505
To rule out any effect of infection on the tumour phenotypes, 506
Drosophila larvae were reared on standard food supplemented with penicillin 507 and streptomycin (100 IU/ml and 100 mg/ml, respectively) ( Figure 1A 
qRT-PCR analysis 511
Total RNA from 7 to 10 whole larvae or tissues collected from 10 to 20 512 larvae (10 larvae for fat body, 20 larvae for trachea) was extracted using 513 TRIzol (Thermo Fisher Scientific), according to the manufacturer's 514 instructions. RNA was treated with Turbo DNA free Kit (Life Technologies 515 LTD) and RNA concentration and quality were monitored using a Nanodrop 516 (Thermo Fisher Scientific). The same amount of total RNA (1µg for whole 517 larvae and fat body or 100ng for trachea) was used to perform the three 518 independent reverse-transcriptions using the High-Capacity cDNA Reverse 519
Transcription Kit (Applied Biosystems). cDNAs were pooled and qPCR was 520 performed using PerfeCTa SYBR green (Quanta Bio), following the 521 manufacturer's instructions. cDNA amplification was monitored with Applied 522
Biosystems 7500 fast instruments. Serial 10-fold dilutions of an external 523 standard were used to produce a standard curve, and RNA samples were 524 included to control for the absence of DNA contamination. rpl32 expression 525 was used to normalize expression levels of target genes. Data was analysed 526 using the Ct method (2 -∆∆ct ). All qPCR experiments were carried out on three 527 to seven independent biological replicates (see figure legends for details) and, 528 larvae were sampled from the same bottle used to analyse the tumour 529 phenotype. GraphPad Prism7 software was used for graphical representation 530 and statistical analysis. Primer targets and sequences are presented in Table  531 supplement 2. 532
533

PCR amplification of genomic DNA 534
To verify the sequence of def sk3 and def sk4 mutants, genomic DNA was 535 extracted from single flies by grinding whole animals with a 200µL pipette tip 536 containing 50µL of squishing buffer (10mM Tris-HCl pH 8.2, 1mM EDTA, 537 25mM NaCl, 200µg proteinase K) followed by incubation at 37°C for 30min. 538
Proteinase K was heat-inactivated at 95°C for 2min. 1µL of genomic DNA was 539 used for PCR amplification using PfuUltra II Fusion DNA Polymerase (Agilent) 540 (for primers see Table supplement 
Annexin V staining and quantification 544
Tumours were dissected in PBS and incubated in Annexin V binding 545 buffer (Fisher Scientific) containing 5% of Alexa Fluor (488nm or 568nm) 546 conjugated Annexin V (Life Technologies LTD) for 10min. Tissues were 547 washed quickly in Annexin V binding buffer and fixed in 4% formaldehyde for 548 20min. Immunostaining, mounting and imaging were then carried out as 549 described above. 550
We used Fiji 2.0.0 software to quantify Annexin V staining at the 551 tumour surface. Maximal Z-projection of whole tumours were generated and 552 the Colour Threshold tool was then used to detect the red pixels that 553
represented Annexin V staining at the surface of tumours. The hue slider was 554 set to include only the red signal, and the brightness slider was adjusted to 555 exclude any background signal. This area was then selected and measured in 556 pixels. 557 558
Synthetic Defensin production and injections 559
The mature Defensin peptide 560 (ATCDLLSKWNWNHTACAGHCIAKGFKGGYCNDKAVCVCRN) was 561 synthesised (over 90% purity) and the purity controlled by Genepep using 562 Ultra Performance Liquid Chromatography/ Mass Spectrometry. We 563 subsequently compared the integrity of synthetic Defensin with authentic 564
Defensin purified from Drosophila hemolymph using two complementary 565 approaches, namely Matrix-Assisted Laser Desorption/Ionization-Mass 566 Spectrometry (MALDI-MS) for molecular mass determination and trypsin 567 digestion followed by nanoLiquid Chromatography/Electrospray Ionization 568 tandem Mass Spectroscopy (nanoLC/ESI MS/MS) for molecular integrity 569 confirmation. Those analyses confirmed the similar mass between natural and 570 synthetic Defensin (respectively provided by Bulet EIRL and Genepep) as well 571 the presence of disulphide bonds within synthetic Def, demonstrating it is the 572 mature peptide (Data not shown). 573
For injection experiments, larvae were collected, washed three times in 574 cold sterile PBS and injected on a fly pad (Flystuff-SLS UK) upon CO 2 575 anaesthesia using Nanoject II and glass capillaries 3.5 inch (Drummond). 576
Larvae were injected with 69nL of PBS containing 7.5nmol of synthetic 577
Defensin or 69nL of PBS only as control. Larvae were then gently transferred 578 into agar/grape juice plates and kept at 25°C. Tumours were dissected 4h 579 after injection and stained for visualization of nuclei and tumour cell death as 580 describe above. 581
582
Statistical analyses 583
All data are presented as mean ± SD and n values are indicated in the 584 figure legends. Statistical analyses were carried out using GraphPad Prism7 585 software and only significant differences are indicated in dot-plots. Survival 586 upon infection was analysed using Log-rank test. qPCR data were analysed 587 using unpaired t-test with a two-tailed p value. Tumour volume and tumour 588 cell death comparing 2 samples were analysed using Mann-Whitney test with 589 a two-tailed p value and the one comparing 3 genotypes were analysed using 590 One-way ANOVA followed by Turkey's multiple comparisons test. Tumour 591 volume from injected larvae was analysed using Two-way ANOVA followed by 592 
